RyboDyn, Inc. is targeting the dark proteome to make new immunotherapies. We are unlocking and validating previously undiscovered, disease-specific targets that will impact the treatment of cancer and autoimmune diseases by driving a new wave of targeted therapeutics. Our "targets-to-assets" therapeutics development program is supported by a scalable, in-house platform for lead discovery and optimization. We aim to deliver first-in-class assets that recognize these targets for treating solid tumors and diseases lacking effective treatment options.

Biotechnology

Health Care

Therapeutics

RyboDyn Inc.

RyboDyn Inc.'s headquarters in San Diego, United States

Description

People (2)

Imad Ajjawi

Brandon Wilding

Jobs